Predictive Value of Histologic Characteristics on Hormone Receptor and HER-2 Status of Patients with Invasive Breast Carcinoma, No Special Type, in an Academic Medical Center

Kevin Elomina, Ma. Carmen Cagampan


Objective: This study aims to assess the predictive value of histologic characteristics in determination of hormone receptor (ER/PR) and HER-2/Neu status in patients with invasive breast carcinoma of no special type (NST).

Methodology: A 4-year review of histopathology and immunohistochemistry reports of women diagnosed with invasive carcinoma NST, was done. Multiple logistic regression was used to determine the association between histologic characteristics and ER and PR status, while multinomial multiple logistic regression was used to determine the association between histologic characteristics and HER-2 status, and that between ER and PR expression, and HER-2 immunoreactivity. All analyses included age, pathologic tumor size, lymph node stage, and lymphovascular space invasion as covariates. 

Results: A total of 137 cases were included in the study. Architectural grade is a significant positive predictor of equivocal HER-2 status (P=0.026). Nuclear grade is a significant negative predictor of ER status (P=0.031). Elston score and Nottingham histologic grade showed no significant association with hormone receptor and HER-2 status. ER status demonstrated no significant association with HER-2 expression, but PR status appears to be a significant negative predictor of a strongly positive HER-2 status (P=0.035). Lymph node stage seems to be a significant positive predictor of an equivocal HER-2 status.

Conclusion: Histologic characteristics can predict ER, PR, and HER-2 status, and interactions between expression of these markers provide some insights regarding the complex genetic interactions in the pathogenesis of breast cancer, and its translation into different histologic phenotypes.



breast carcinoma, histology, immunohistochemistry

Full Text:

Abstract HTML PDF


Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. PMID: 20404251. PMCID: PMC2881855.

Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clincal practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. PMID: 24101045.

Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359–77. PMID: 13499785. PMCID: PMC2073885.

Mittal A, Prasad CSBR, Sreeramulu PN, Srinivasan D, Naveedahmed K, Ruta UJ. Histopathological grade versus estrogen and progestron receptor status in carcinoma breast- a single center study. Open Access J Surg. 2017;4(3):10–3. 10.19080/OAJS.2017.04.555639.

Dayal A, Shah RJ, Kothari S, Patel SM. Correlation of Her-2/neu status with estrogen, progesterone receptors and histologic features in breast carcinoma. Ann Pathol Lab Med. 2016;3(5):8.

Geethamala K, Srinivasa M V., Vani BR, Sudha R. Histopathological grade versus hormone receptor status in breast carcinoma-treasure the past. Int J Biomed Res. 2015;6(7):466–71. 10.7439/ijbr.v6i7.2203.

Iqbal J, Abukhatir M, Shafi AA, Alyahya GM, Alharthi BN. Hormone receptor status of breast cancer in patients of different age groups, lymph node status histological type and tumor grade, an experience at King Fahad Medical City, Riyadh. Pak J Surg. 2014;30(4):296–300.

Mostafa MG, Larsen MT, Love RR. Estrogen receptor, progesterone receptor, and Her-2/neu oncogene expression in breast cancers among Bangladeshi women. J Bangladesh Coll Physicians Surg. 2010;28(3):157–62. PMID: 22279410. PMCID: PMC3263928. NIHMSID: NIHMS270134.

Pathak T, Bashyal R, Pun C, et al. Estrogen and progesterone receptors in breast cancer. J Pathol Nepal. 2011;1(2):100–3.

Azizun-Nisa, Bhurgi Y, Raza F, Kayani N. Comparison of ER, PR & HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pacific J Cancer Prev. 2008;9(4):553–6. PMID: 19256737.

Peduzzi P, Concato J, Kemper E, Holford TR, Feinstem AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9. PMID: 8970487.

Gupta D, Gupta V, Marwah N, et al. Correlation of hormone receptor expression with histologic parameters in benign and malignant breast tumors. Iran J Pathol. 2015;10(1):23–34. PMID: 26516322. PMCID: PMC4539786.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10. PMID: 1757079.

Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. PMID: 28294295.

Allison KH. Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol. 2012;138(6):770–80. PMID: 23161709.

Kabel AM. Tumor markers of breast cancer: new prospectives. J Oncol Sci. 2017;3(1):5–11.

Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 2012;357(1–2):18–29. PMID: 21952082. PMCID: PMC3272316.

You K, Park S, Ryu JM, et al. Comparison of core needle biopsy and surgical specimens in determining intrinsic biological subtypes of breast cancer with immunohistochemistry. J Breast Cancer. 2017;20(3):297–303. PMID: 28970856. PMCID: PMC5620445.


  • There are currently no refbacks.